Zobrazeno 1 - 10 of 1 283 pro vyhledávání: '"Gatfield, J."'
1
Akademický článek
Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder.
Autor: Steiner MA; CNS Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Botticelli L; Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy., Bergamini G; CNS Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Micioni Di Bonaventura E; Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy., Gatfield J; CNS Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Williams JT; CNS Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Treiber A; CNS Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Vaillant C; CNS Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Cifani C; Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy., Micioni Di Bonaventura MV; Pharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.
Publikováno v: The International journal of eating disorders [Int J Eat Disord] 2024 Jul; Vol. 57 (7), pp. 1418-1432. Date of Electronic Publication: 2024 Mar 08.
Zobrazit plný text záznamu
3
Akademický článek
A uniquely efficacious type of CFTR corrector with complementary mode of action.
Autor: Marchesin V; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Monnier L; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Blattmann P; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Chevillard F; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Kuntz C; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Forny C; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Kamper J; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Studer R; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Bossu A; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Ertel EA; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Nayler O; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Brotschi C; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Williams JT; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland., Gatfield J; Idorsia Pharmaceuticals Ltd., 4123 Allschwil, Switzerland.
Publikováno v: Science advances [Sci Adv] 2024 Mar; Vol. 10 (9), pp. eadk1814. Date of Electronic Publication: 2024 Mar 01.
Zobrazit plný text záznamu
4
Akademický článek
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials.
Autor: Williams JT; Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland., Bolli MH; Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland., Brotschi C; Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland., Sifferlen T; Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland., Steiner MA; Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland., Treiber A; Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland., Gatfield J; Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland., Boss C; Drug Discovery, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Feb 22; Vol. 67 (4), pp. 2337-2348. Date of Electronic Publication: 2024 Feb 08.
Zobrazit plný text záznamu
5
Akademický článek
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.
Autor: Brotschi C; Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Development Hegenheimermattweg 91 4123 Allschwil Basel-Landschaft Switzerland., Bolli MH; Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Development Hegenheimermattweg 91 4123 Allschwil Basel-Landschaft Switzerland., Gatfield J; Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Development Hegenheimermattweg 91 4123 Allschwil Basel-Landschaft Switzerland., Roch C; Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Development Hegenheimermattweg 91 4123 Allschwil Basel-Landschaft Switzerland., Sifferlen T; Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Development Hegenheimermattweg 91 4123 Allschwil Basel-Landschaft Switzerland., Treiber A; Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Development Hegenheimermattweg 91 4123 Allschwil Basel-Landschaft Switzerland., Williams JT; Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Development Hegenheimermattweg 91 4123 Allschwil Basel-Landschaft Switzerland., Boss C; Idorsia Pharmaceuticals Ltd, Drug Discovery and Preclinical Development Hegenheimermattweg 91 4123 Allschwil Basel-Landschaft Switzerland.
Publikováno v: RSC medicinal chemistry [RSC Med Chem] 2023 Nov 24; Vol. 15 (1), pp. 344-354. Date of Electronic Publication: 2023 Nov 24 (Print Publication: 2024).
Zobrazit plný text záznamu
6
Akademický článek
The metabolism of the dual orexin receptor antagonist daridorexant.
Autor: Treiber A; Department of Non-clinical Pharmacokinetics and Metabolism, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Delahaye S; Department of Non-clinical Pharmacokinetics and Metabolism, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Weigel A; Department of Non-clinical Pharmacokinetics and Metabolism, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Aeänismaa P; Department of Non-clinical Pharmacokinetics and Metabolism, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Gatfield J; Department of Biology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland., Seeland S; Department of Non-clinical Pharmacokinetics and Metabolism, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
Publikováno v: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2023 Mar; Vol. 53 (3), pp. 173-183. Date of Electronic Publication: 2023 May 11.
Zobrazit plný text záznamu
7
Akademický článek
A dispensable SepIVA orthologue in Streptomyces venezuelae is associated with polar growth and not cell division.
Autor: Sen, Beer Chakra1 (AUTHOR), Mavi, Parminder Singh1 (AUTHOR), Irazoki, Oihane2 (AUTHOR), Datta, Susmita1 (AUTHOR), Kaiser, Sebastian1 (AUTHOR), Cava, Felipe2 (AUTHOR), Flärdh, Klas1 (AUTHOR) klas.flardh@biol.lu.se
Publikováno v: BMC Microbiology. 11/18/2024, Vol. 24 Issue 1, p1-15. 15p.
Zobrazit plný text záznamu
8
Akademický článek
Role of Sphingosine-1-Phosphate Signaling Pathway in Pancreatic Diseases.
Autor: Fu, Fei1,2 (AUTHOR) fufei9940@wchscu.cn, Li, Wanmeng2 (AUTHOR) 2023224070047@stu.scu.edu.cn, Zheng, Xiaoyin2 (AUTHOR) 2022224070024@stu.scu.edu.cn, Wu, Yaling2 (AUTHOR), Du, Dan1,2 (AUTHOR) dudan@wchscu.cn, Han, Chenxia1 (AUTHOR) dudan@wchscu.cn
Publikováno v: International Journal of Molecular Sciences. Nov2024, Vol. 25 Issue 21, p11474. 25p.
Zobrazit plný text záznamu
9
Akademický článek
The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
Autor: Boss C; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Gatfield J; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Brotschi C; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Heidmann B; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Sifferlen T; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., von Raumer M; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Schmidt G; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Williams JT; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Treiber A; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Roch C; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland.
Publikováno v: ChemMedChem [ChemMedChem] 2020 Dec 03; Vol. 15 (23), pp. 2286-2305. Date of Electronic Publication: 2020 Oct 28.
Zobrazit plný text záznamu
10
Akademický článek
From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs.
Autor: Brotschi C; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Bolli MH; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Gatfield J; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Heidmann B; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Jenck F; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Roch C; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Sifferlen T; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Treiber A; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Williams JT; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland., Boss C; Drug Discovery and Preclinical Research & Development, Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123, Allschwil, BL, Switzerland.
Publikováno v: ChemMedChem [ChemMedChem] 2020 Mar 05; Vol. 15 (5), pp. 430-448. Date of Electronic Publication: 2020 Jan 16.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje